Thank you very much. Thanks for joining today's conference. With me, I have our CFO Agneta Palmér who will present the financials in a moment, but let's get started. We can move directly over to page number two, please. And let's start by looking at some of the highlights and key takeaways from the second quarter of 2024.
Net sales increased by 15.7% in the second quarter. The organic growth part of this was 8.9%. Order intake for Getinge increased by 14.4%, and the organic part here was 7.8%, thanks to positive development in all our three business areas. Adjusted gross margins improved in all business areas, and the adjusted EBIT margin for the group improved by 4.9 percentage points year-on-year. This is mainly coming from the weak comparison from last year, plus healthy growth mix and price, mitigating the negative effects from inflation that we still see.
These are effects that we continuously address through productivity improvements and structural changes when and where needed. All in all, this contributes to a solid financial position that enables investments in profitable growth also going forward. We can then move over to page number three, please. So let's take a look at some of wkey activities that will drive future growth and profitability. In terms of our offerings and customers, I'd like to mention that in the quarter we launched the Poladus 150.
It's an advanced low-temperature sterilizer that meets an important need for our customers. From a regulatory perspective, we received FDA 510(k) clearance for our Advanta V12 Clinical Guidance digital offering, which enables digital clinical decision support. And we also had an EU MDR approval for our coverage. Stent system advanced to V12. Within Life Science, the GW 888 Neo washer was launched, which contributes to increased efficiency in the clean room, and it also reduces water consumption by 20%.
In addition to this, we had a new version of our DPT beta bag launched, and this version is made from a larger portion of renewable materials in the quarter as well. On May 15th, we had a capital market update presenting the updated adjusted earnings per share target of an average growth of over 12% in the years 2024 through 2028. When it comes to sustainability and quality, the quality improvement work linked to the Balloon Pump Cardio Save and the Access System Cardio Health. As previously communicated, we have actively promoted in the US these products, but we are still able voluntarily to sell and deliver if our customers see no good alternative.
We are in close dialogue with customers and authorities, but it's too early to single out any specific trend in sales when it comes to this. In the quarter, we also submitted an application for CE marking of the new packaging for the ECMO therapy consumables, HLS and PLS sets. We can then move over to over to page number four please. So as I mentioned earlier, the order intake grew by 14.4% where of 7.8% organically and net sales increased by 15.7%, where of 8.9%. Organically and regionally oriented growth was strong in EMEA and Asia Pacific, and the decline in organic order intake in the Americas is mainly due to a softer quarter for Life Science and for surgical workflows.
All regions grew net sales organically in the quarter, mainly driven by an improvement in acute care therapies compared with the challenging Q2 of last year. You can then move over to page five, please. So all of this combined takes us to the outlook, where we reiterate our previous guidance for 2024. We expect organic net sales growth to be 2 to 5%. And in addition to this, we expect recent acquisitions to contribute 3 to 5 percentage points of growth. And this is unchanged. We can move to page number six please.
And we'll take a closer look at the order intake of the second quarter. So per business area in acute care therapies, we had 8% organic growth. This increase is mostly driven by critical care, cardiopulmonary, and cardiac surgery. Life science had an 18.4% organic growth. And, this was after a strong quarter in sterile transfer.
The development in bioprocessing was still weak, as you've seen in the earlier quarters as well. In surgical workflows, the growth was 3.4% organically with an increase in all product categories except for digital health solutions. So in summary, for the group, this means 7.8% organic order intake growth and in actuals, 14.4%. You can then move to page number seven, please.
And then from a sales perspective, a noticeable increase was seen. Organic net sales increased sharply following higher sales of consumables in both cardiopulmonary and cardiac assist compared to the difficult Q2 last year. And life science organic net sales decreased by 13.1% in the quarter, mainly due to washer, disinfectants, sterilizer and sterile transfer. However, sales from high purity processes in New England in the quarter make up for almost all of this.
And when it comes to surgical workflows, organic net sales decreased slightly, mainly due to lower sales in infection control. The acquisition of Health Mark continues to contribute to growth in a material way; overall, for the group, acquisitions contributed an increase in net sales of 499 million in the quarter. Currency had a -5 million SEK impact on net sales for the group in the quarter. And when it comes to revenue from consumables, this was strong in the quarter, contributing to high growth in recurring revenue. Let's move over to page number eight.
And if we take a closer look at the gross margin and gross profit, gross profit increased by 837,000,006 to 4,151,000,006 in the quarter, where foreign exchange effects impacted by plus 35 million SEK. All business areas improved their adjusted gross margin, leading to a 3.8 percentage point increase for the group relative to last year's lower comparatives. A mix of price absorption and FX had a positive impact, while cost inflation still erodes the margin, and this is something we continue to address.
For acute care therapies, the adjusted gross margin improved by 3.6 percentage points, mainly due to increased sales, the product mix inside the business area, and currency. This was partly offset by higher costs for input goods, employees, and ongoing quality improvement efforts with regard to cardiac assist and cardiopulmonary. For life science, the adjusted gross margin increased by 2.8 percentage points due to a favorable mix, price improvements, and currency. And this was partly offset by lower volumes and low absorption in surgical workflows. The adjusted gross margin increased by 2.8 percentage points, mainly as a result of acquisitions and price increases. And with that, we'll move over to page number nine. And I hand over to you.